The Role of And-1 in DNA Damage Response

And-1 在 DNA 损伤反应中的作用

基本信息

  • 批准号:
    8848359
  • 负责人:
  • 金额:
    $ 32.89万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2019-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): DNA damage response (DDR) is a complex signal transduction pathway, which is extremely important to maintain genomic stability and prevent carcinogenesis by counteracting the deleterious effects of DNA damage. In response to replication stress or UV irradiation, the primary event of DDR is to activate kinases ATR and Chk1, which in turn trigger multiple physiological processes, including DNA synthesis inhibition, DNA repair, and cell cycle delay, transcription, etc. ATR plays a key role in Chk1 activation and DNA synthesis inhibition in response to DNA damage. However, how ATR coordinates with various DDR components to activate Chk1 and how ATR targets replication apparatus to inhibit DNA synthesis remain largely unknown in mammalian cells. We have demonstrated that human And-1 acts as a key component of replisome at replication forks for DNA replication. We now have solid preliminary data indicating that And-1 is also involved in the regulation of checkpoint and DNA synthesis in response to DNA damage. Thus, elucidating the role of And-1 in DDR will fill in critical knowledge gaps of DDR signaling. Building upon our recently published work and our extensive new data, in this proposal we described a series of innovative, hypothesis-driven studies to elucidate how human And-1 regulates checkpoint activation and DNA synthesis in response to UV irradiation and replication stress. First, we will determine the mechanism of how And-1 is recruited to DNA damage sites using both biochemical and structural analyses. Second, we will determine how And-1 acts as a unique replisome component to regulate checkpoint activation by impacting interplay among multiple key DDR components including ATR, Rad17, Claspin, and Timeless-Tipin at stalled replication forks using molecular and structural analyses. Finally, we will determine mechanism by which And-1 governs DNA synthesis in response to DNA damage by carrying out an innovative approach that combines multiple cutting edge technologies including single-molecule analyses, iPOND, and mass spectrometry. Given that targeting the circuitry of DNA damage response has been a key focus for the development of anti-cancer drugs, proposed work will not only advance the field by identifying new components and acquiring in-depth mechanistic understanding of DNA damage response, but also provide us with new strategies for the development of highly specific anti-cancer therapies targeting And-1 or And-1-dependent processes.
描述(申请人提供):DNA损伤反应(DDR)是一种复杂的信号转导途径,通过抵消DNA损伤的有害影响,对维持基因组稳定和预防癌症发生极其重要。在对复制胁迫或紫外线辐射的反应中,DDR的主要事件是激活ATR和Chk1,进而触发多种生理过程,包括DNA合成抑制、DNA修复、细胞周期延迟、转录等,ATR在Chk1激活和DNA合成抑制中发挥关键作用。然而,在哺乳动物细胞中,ATR如何与不同的DDR组分协调激活Chk1,以及ATR如何靶向复制装置以抑制DNA合成在很大程度上仍是未知的。我们已经证明了人类和-1在DNA复制的复制叉处作为复制体的关键组成部分。我们现在有确凿的初步数据表明,And-1也参与了检查点和DNA合成的调节,以应对DNA损伤。因此,阐明和-1在DDR中的作用将填补DDR信号转导的关键知识空白。在我们最近发表的工作和我们广泛的新数据的基础上,在这个提案中,我们描述了一系列创新的、假设驱动的研究,以阐明人类和-1如何调节检查点激活和DNA合成,以响应紫外线照射和复制压力。首先,我们将利用生化和结构分析来确定和-1如何被招募到DNA损伤部位的机制。其次,我们将使用分子和结构分析来确定And-1如何作为一个独特的复制体组件,通过影响包括ATR、Rad17、Claspin和Timless-Tipin在内的多个关键DDR组件之间的相互作用来调节检查点激活。最后,我们将通过开展一种创新的方法,结合包括单分子分析、iPOND和质谱学在内的多种尖端技术,确定和-1调控DNA合成以应对DNA损伤的机制。鉴于靶向DNA损伤反应通路一直是抗癌药物开发的一个关键焦点,所提出的工作不仅将通过识别新的成分和深入了解DNA损伤反应的机制来推动该领域的发展,而且还将为靶向AND-1或AND-1依赖过程的高度特异性抗癌治疗的发展提供新的策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wenge Zhu其他文献

Wenge Zhu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wenge Zhu', 18)}}的其他基金

The role of And-1 in nucleotide excision repair
And-1在核苷酸切除修复中的作用
  • 批准号:
    10362967
  • 财政年份:
    2022
  • 资助金额:
    $ 32.89万
  • 项目类别:
The role of And-1 in nucleotide excision repair
And-1在核苷酸切除修复中的作用
  • 批准号:
    10576346
  • 财政年份:
    2022
  • 资助金额:
    $ 32.89万
  • 项目类别:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
靶向范可尼贫血途径克服卵巢癌铂类药物耐药性
  • 批准号:
    10392909
  • 财政年份:
    2021
  • 资助金额:
    $ 32.89万
  • 项目类别:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
靶向范可尼贫血途径克服卵巢癌铂类药物耐药性
  • 批准号:
    10599218
  • 财政年份:
    2021
  • 资助金额:
    $ 32.89万
  • 项目类别:
Targeting Fanconi Anemia pathway to overcome platinum drug resistance in ovarian cancer
靶向范可尼贫血途径克服卵巢癌铂类药物耐药性
  • 批准号:
    10117536
  • 财政年份:
    2021
  • 资助金额:
    $ 32.89万
  • 项目类别:
The Regulation of Cisplatin resistance in ovarian cancer
卵巢癌顺铂耐药的调控
  • 批准号:
    8916657
  • 财政年份:
    2014
  • 资助金额:
    $ 32.89万
  • 项目类别:
The Regulation of Cisplatin resistance in ovarian cancer
卵巢癌顺铂耐药的调控
  • 批准号:
    8673956
  • 财政年份:
    2014
  • 资助金额:
    $ 32.89万
  • 项目类别:
The Role of And-1 in DNA Damage Response
And-1 在 DNA 损伤反应中的作用
  • 批准号:
    9271933
  • 财政年份:
    2014
  • 资助金额:
    $ 32.89万
  • 项目类别:
The Regulation of Cisplatin resistance in ovarian cancer
卵巢癌顺铂耐药的调控
  • 批准号:
    9301488
  • 财政年份:
    2014
  • 资助金额:
    $ 32.89万
  • 项目类别:
The Role of And-1 in DNA Damage Response
And-1 在 DNA 损伤反应中的作用
  • 批准号:
    8691032
  • 财政年份:
    2014
  • 资助金额:
    $ 32.89万
  • 项目类别:

相似海外基金

Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 32.89万
  • 项目类别:
Eliminate the difficulty of venous puncture in patients receiving antineoplastic agents - Development of a new strategy for the prevention of induration-
消除接受抗肿瘤药物的患者静脉穿刺的困难 - 制定预防硬结的新策略 -
  • 批准号:
    16K11932
  • 财政年份:
    2016
  • 资助金额:
    $ 32.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms of the antineoplastic agents inhibiting DNA replication and their applications to cancer patient treatmen
抗肿瘤药物抑制DNA复制的分子机制及其在癌症患者治疗中的应用
  • 批准号:
    19591274
  • 财政年份:
    2007
  • 资助金额:
    $ 32.89万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PNET EXPERIMENTAL THERAPEUTICS--ANTINEOPLASTIC AGENTS AND TREATMENT DELIVERY
PNET 实验治疗——抗肿瘤药物和治疗实施
  • 批准号:
    6346309
  • 财政年份:
    2000
  • 资助金额:
    $ 32.89万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    2720213
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
抗肿瘤药物药理学培训
  • 批准号:
    6513197
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    7101017
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
Training in Pharmacology of Antineoplastic Agents
抗肿瘤药物药理学培训
  • 批准号:
    6894842
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    2885074
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
酪氨酸激酶抑制剂作为抗肿瘤剂
  • 批准号:
    6174221
  • 财政年份:
    1999
  • 资助金额:
    $ 32.89万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了